SkyCell, a Zug, Switzerland-based technology company empowering the pharmaceutical supply chain, raised $116M in Series D funding.
The round consisted of US$59M from Tybourne Capital Management and CCI and a US$57M equity investment from Catalyst.
The company intends to use the funds for the continued expansion of its global footprint with a key focus on growth across the US and Asia.
Led by CEO Richard Ettl, SkyCell is a technology company innovating the pharmaceutical supply chain through a combination of proprietary software, hardware, and big data. It is a manufacturer of temperature-controlled door-to-door container solutions that allow pharma companies to optimise their supply chain by reducing, and even predicting, the risks associated with delivering sensitive drugs by air. Its proprietary software solution combines simulation data with operational data (S+O data), enabling pharma companies to have real-time, end-to-end oversight of every shipment around the world getting drugs to consumers.
Its technologies protect healthcare systems by reducing in-transit failure rate to a market-leading low of less than 0.05% temperature excursions and reduce the CO2 impact of each shipment by almost half the average rate. SkyCell is a climate-neutral company (Scope 1 & 2 compensated) and has committed to the goal of end-to-end net-zero by 2040.
FinSMEs
25/06/2024